Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2015.
Armune BioScience Inc. granted AEterna Zentaris Inc. rights to sell its Apifiny prostate cancer diagnostic to designated medical professionals in the US. For those tests that it markets, AEterna gets sales commissions. (Dec.)
Apifiny is the only cancer-specific non-PSA blood test for prostate cancer. It tests for autoantibodies produced by the immune system...